Alexithymia further represents a complex construct that goes beyond the basic definition of the mere inability to describe one's own emotions, but rather predicts how an individual experience himself and his emotions, as well as the world around him, and speaks of a lack of the possibility of symbolism, which will mean that these patients tend to focus on concrete topics [
8,
9]. If these patients are inclined to a concrete, non-phantasmatic interpretation of internal and external reality and then we may consider alexithymia to be very pronounced [
8,
10]. Diabetes mellitus type 2 represents a very demanding and difficult diagnosis regarding the importance of discipline not only when taking medication, but also maintaining a healthy lifestyle. Thus, a person with diabetes mellitus type 2 must pay attention to the therapy regimen, caloric intake, qualitative food intake, if on insulin therapy, have the necessary equipment in every situation, pay attention to foot care, etc. [
11,
12]. Eating represents a very essential and important sociocultural role, and such a level of engagement with one's own illness certainly makes an individual tired and frustrated after a while and can lead to some mental health problems [
13,
14]. Also, things like continuous glucose monitor implants facilitate disease control and comfort, which is still relatively challenging in Croatia.[
15] However, CGM implants still change the external appearance and the patient may feel different, ashamed or stigmatized, which can also be a problem for a certain number of patients. A person with diabetes mellitus can thus find her/himself in a rather unfavorable position. It should be noted that for some people, food represents a certain type of escape from reality and comfort. It can also be present with symptoms associated with atypical depression [
9,
16], but for some people, food also represents a small joy during the day, such as eating something sweet (a cake or the like). A person with diabetes mellitus type 2 must also pay attention to this. This alone brings us to the very important concept of one's own awareness and reaction to the disease and the recognition of one's own emotions and conditions related to the reaction to a disease such as diabetes mellitus. Alexithymia in patients with diabetes mellitus has been investigated for some time, but the results and conclusions are still sometimes contradictory and the discussion about the exact connection and causal effect is still being investigated. Melin et al. 2017 in a study comparing patients with DM type 1 and 2 reported that depression is strongly associated with alexithymia in patients with DM type 2 and that this is attributable to features of atypical depression since other results indicated no association with anxiety and elevated levels secretion of cortisol. Furthermore, their results indicate that people with DM type 2 and depressive symptoms also have a high prevalence of obesity [
9]. Friedman et al. found that alexithymia is associated with depression in type 1 DM patients as well [
17]. Dincer et al. in 2021 published a paper in which during 2020 (the pandemic period) they studied the connection between alexithymia, depressive symptoms and changes in sexual behavior in patients with DM type 2, and their results show that after diabetes, 83.3% of patients had impaired sexual functioning, which could be associated with high levels of depressive and anxiety symptoms, especially during a pandemic, and alexithymia stands out as a possible connection [
12]. Our team's research from 2021 revealed that approximately one third of obese patients have sexual dysfunction and that this association is more pronounced in female obese patients, as well as those who have more pronounced anxiety and depressive symptoms [
18]. All of the above indicates that difficulties in sexual functioning could be related to depressive symptoms in patients with DM type 2 and obesity, where alexithymia could play a significant role, which is still insufficiently defined. The connection between cognition and alexithymia is increasingly being investigated, including in patients with DM type 2. Hintistan et al. 2013 in patients with DM type 2 older than 60 years without a psychiatric diagnosis found the presence of alexithymia in 75.8% of patients and the association was not related to professional status or level of education. Furthermore, other studies also question whether alexithymia is only a consequence of a certain cognitive deficit, especially in patients with obesity and DM type 2 [
11,
19,
20]. Martino et al. note in their review that the prevalence of alexithymia in patients with DM type 2 ranges from 25-50% which is noteworthy as they found that alexithymia is a predictor of poor glycemic control. They hypothesize that poor awareness of bodily sensations in alexithymic patents negatively impacts coping strategies in the management of DM type 2 in both self-care and disease knowledge. They also highlight how patients with alexithymia may be less prone to recognize their illness and seriously follow their doctors’ instructions. On the other hand, they explain that poor glycemic control might negatively impact cognitive and emotional processing, resulting in greater alexithymia levels overall which might explain increased hospitalization rates some studies found in patients that found a correlation between alexithymia and diabetes. Martino et al. also note the correlation of alexithymia with depression and anxiety which might prevent the patient making sense of the illness without adequate psychotherapeutic intervention [
14]. Lemche et al. conducted a study exploring the connection between alexithymic symptoms in patients with metabolic syndrome and those patients developing DM type 2. They found that alexithymia severity is a predictor of DM type 2 in patients with metabolic syndrome as well as that alexithymia statistically significantly predicts other indicators of obesity like BMI and waist girth and risk factors like dyslipidemia, hypertension and microalbuminuria, all relevant biomarkers in long term outcomes in metabolic syndrome patients [
21]. These findings collectively highlight the potential relationship between alexithymia and T2DM, as well as their impact on glycemic control and emotional well-being. However, it's important to note that research in this area may vary in terms of study populations and methodologies, and more research may be needed to further understand the complex interactions between alexithymia, T2DM, and related factors. (
Table 2).
Table 2.
This table summarizes findings from various studies regarding the relationship between alexithymia and Type 2 Diabetes Mellitus (T2DM), as well as their potential impact on glycemic control and related factors.
Study |
Results |
Friedman et al. (2003)[17] |
Alexithymia isn’t correlated with glycemic control |
Lemche et al. (2014)[21] |
Alexithymia is substantial indicator of T2DM and cardiovascular risks in patients with metabolic syndrome |
Luca et al. (2014)[13] |
Alexithymic patients presented higher HBA1c levels compared to non- alexithymic ones |
Avci et al. (2016)[16] |
Alexithymia was 2,09 times higher among T2DM patients who had HbA1c ≥ 7 % |
Melin et al. (2017)[9] |
Depression was associated with alexithymia in T2DM patients |
Martino et al. (2020)[14] |
Patients with T2DM reflected greater values of alexithymia |
Celik et al. (2022)[22] |
Majority of T2DM patients showed signs of alexithymia and positive relationship between HBA1c and alexithymia score was found |
A cross-sectional study by Avci & Kelleci, which enrolled 326 DM2 patients (37.3% determined to have alexithymia), reported that alexithymia was 2.09 times higher among those who had worse glycaemia control (HbA1c ≥7.0% vs <7.0% group), as well as 3.77 and 2.57 times higher for those in whom anxiety (≥11 vs ≤10) and depression (≥8 vs ≤7) were more expressed, respectively. Latter is obviously an interesting finding; however, the obtained results should be interpreted accordingly bearing in mind the study methodology [
16]. What is more, as per Luca et al. data, alexithymia more than depression influenced glycemic control, and HbA1c was only significantly associated (logistic regression), with alexithymia and insulin therapy, which clearly highlights the importance of this topic [
13]. To deduce, a well-summarized body of literature within the Martino et al. systematic review, revealed a strong correlation between alexithymia, HbA1c and fasting blood glucose levels; 0.75 and 0.77 (for TAS-20 total scores), respectively. Also, significantly higher levels of HbA1c and blood glucose were present among alexithymic (25-50% of DM2 population in general) compared to the non-alexithymic participants [
14]. To the best of our knowledge, the are no RCT designs yet, so we can only talk on association, but not on causality. However, we can speculate that improving glycemic control, and decreasing anxiety and depression levels, might result in better alexithymia control, and
vice versa. All thing considered, it is evident that management of patients living with DM2 should be arranged to include psychopathological alterations screening and mental health care services for those at risk in order to improve both DM2 control as well as quality of life [
14,
23]. On the other hand, well-management of alexithymia is a cornerstone for improving the psychiatric treatment outcomes in general also [
24,
25]; thus, it can be seen as a strong 'knot' within the DM2-psychiatry vicious circle. To clarify, alexithymia is implicated in a wide variety of psychological problems (depression and schizophrenia), emotional deficits in autism spectrum disorder, suicidality, increased psychosomatic complaints, and elevated mortality rates; thus achieving optimal/rational and personalized antidepressant, antipsychotic, mood stabilizer, and anxiolytic prescribing (alongside cognitive-behavioral therapy and psychodynamic therapy) is a hard, but indispensable task for clinicians working with patients in such a setting [
26]. Simultaneously, it is of utmost importance to choose an optimal antihyperglycemic therapeutic approach (always, but especially in alexithymic patients), bearing in mind the efficacy/effectiveness, safety profile, comorbidity profile (both potential benefits and harms), as well as medication adherence rates, and costs [
27].